Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

INTSBullishCorporate Developmentsnews

High materiality8/10

Promising Early Data from INVINCIBLE-4 Study Could Boost INT230-6's Outlook

Mar 12, 2026, 7:33 AM EDT2 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The strong preliminary data on pCR rates and safety profile against current standards suggests heightened investor interest, similar to past biotech scenarios where positive trial results led to stock surges.

AI summary

What happened, with direct paths to the underlying reporting

Preliminary results from the INVINCIBLE-4 Study reveal that patients receiving INT230-6 show significantly higher pathological complete response rates and fewer severe adverse events compared to those receiving standard of care. With the submission of a protocol amendment to Swiss authorities for resumed enrollment, there is potential for accelerated pathways to approval, which could positively impact investor sentiment towards INTS.

71.4% of INT230-6 patients achieved pathological complete response versus 33% in SOC arm.
Cohort A had 44% fewer severe adverse events compared to SOC arm.
Enrollment in INVINCIBLE-4 Study paused due to skin irritations, now set to resume.
Exciting data prompts filing with Swiss authorities for continued trial enrollment.
Intended total enrollment is up to 61 patients by trial's completion.

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.